蒽环类抗肿瘤药诱发心肌病1例及文献复习  

Anthracycline-induced cardiomyopathy in cancer therapy:one case report and literature review

作　　者：林莹[1,2] 李彦华[1] 郭新红[1] 徐勇[1] 李玉峰[1] 刘昱圻[1] 金荣杰[1] LIN Ying LI Yan-Hua GUO Xin-Hong XU Yong LI Yu-Feng LIU Yu-Qi JIN Rong-Jie(Department of Cardiology, Chinese PLA General Hospital, Beijing 100853, China Department of Cardiology, Hainan Branch of Chinese PLA General Hospital, Sanya 572013, China)

机构地区：[1]解放军总医院心血管内科,北京100853 [2]解放军总医院海南分院心血管内科,三亚572013

出　　处：《中华老年多器官疾病杂志》2017年第1期61-63,共3页Chinese Journal of Multiple Organ Diseases in the Elderly

摘　　要：回顾性分析1例病情特殊的扩张性心肌病患者,65岁女性,之前无心脏病史。主要表现为胸闷、气短,相关检查提示扩张性心肌病,既往因乳腺癌接受蒽环类抗肿瘤药治疗。回顾之前发表的其他病例数据,总结蒽环类抗肿瘤药诱导心肌病的相关诊治经验,采用规范化、个体化治疗后患者症状缓解。因此,应用蒽环类抗肿瘤药治疗时应监测、防治由化疗药物导致的心脏毒性。若病变发展为慢性心脏毒性表现,则尽早应用改善心肌预后的药物。We retrospectively analyzed a particular case of dilated cardiomyopathy, that is,a 65-year-old woman who had no history of heart disease mainly presenting chest tightness and shortness of breath. Related examinations suggested dilated cardiomyopathy, and the patient had ever received anthracycline drugs for breast cancer treatment. We reviewed related literatures and summarized the experience on diagnosis and treatment of anthracycline-induced cardiomyopathy. After standardized and individualized treatment, her symptoms were relieved. Therefore, we should monitor cardiac function during anthracyclines administration to prevent and treat cardiac toxicity caused by chemotherapy drugs. If the condition developes into chronic heart disease, the drugs to improve myocardial prognosis should be used as early as possible.

关 键 词：蒽环类抗肿瘤药 抗肿瘤治疗 心脏毒性 心肌病 

分 类 号：R979.1[医药卫生—药品]